Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for early breast cancer.

person Takayuki Kinoshita NHO Tokyo Med Ctr, Tokyo, Japan info_outline Takayuki Kinoshita, Shin Takayama, Masato Takahashi, Tomomi Fujisawa, Manabu Futamura, Naohito Yamamoto, Tadahiko Shien, Kenjiro Aogi, Tatsuya Ohnishi

Authors person Takayuki Kinoshita NHO Tokyo Med Ctr, Tokyo, Japan info_outline Takayuki Kinoshita, Shin Takayama, Masato Takahashi, Tomomi Fujisawa, Manabu Futamura, Naohito Yamamoto, Tadahiko Shien, Kenjiro Aogi, Tatsuya Ohnishi Organizations NHO Tokyo Med Ctr, Tokyo, Japan, National Cancer Center Hospital, Tokyo, Japan, Hokkaido University Hospital, Hokkaido, Hokkaido, Japan, Gunma Prefectural Cancer Center, Ohta, Japan, Gifu University, Graduate School of Medicine, Gifu-Shi, Japan, Chiba Cancer Center, Chiba, Japan, Okayama university hospital, Okayama-Shi, Japan, NHO Shikoku Cancer Center, Matsuyama-Shi, Japan, National Cancer Center Hospital East, Kashiwa, Japan Abstract Disclosures Research Funding Other Japan Agency for Medical Research and Developement Background: Early-stage breast cancer is increasingly detected by screening mammography, and we aim to establish radiofrequency ablation therapy (RFA) as a minimally invasive, cost-efficient, and cosmetically acceptable local treatment. In our Phase I study, localized tumors with a maximum diameter of 2 cm, preoperatively diagnosed by imaging and histopathology, were treated with RFA. A 90% complete ablation rate was confirmed histopathologically. Our phase II multicenter study of RFA without resection for early breast cancer will evaluate the long-term safety and efficacy of RFA as well as its cosmetic results, which are a perceived advantage of this technique. Methods: From Nov. 2009 to Nov. 2012, 58 patients with early-stage breast cancer received non-surgical RFA therapy. Patients had localized solitary N0 tumors with a maximum diameter of 1 cm. In our experimental therapy, a radiofrequency electrode needle is inserted through the skin into the breast lesion under imaging guidance, followed by thermal ablation with radiofrequency waves. RFA will be conducted under general anesthesia. The Cool-tip™ RF Ablation Single Electrode Kit (Medtronic, CO, USA) will be used to standardize the evaluation of the ablation effect. They underwent RFA and SNB under general anesthesia and adjuvant therapy and breast radiation. Follow-up evaluation for residual tumor at 3, 6, and 12 months after RFA included clinical examination, diagnostic imagings and vacuum-assisted biopsy. Surgical resection was recommended for patients with suspected residual disease or incomplete ablation. The primary endpoint was the frequency of adverse events. Secondary endpoints included the complete ablation rate and ipsilateral breast relapse-free rate. Results: The follow-up period ranged from 15 to 109 months (median, 85 months). The 57 patients completed the non-surgical RFA procedure and underwent diagnostic imaging and needle biopsy after 3 months. Seven patients with suspected incomplete ablation underwent surgical resection; incomplete ablation was confirmed in 5 (8.6%, 2 with invasive and 3 with non-invasive ductal carcinoma). During subsequent follow-up, 1 patient each was diagnosed with contralateral breast cancer and ipsilateral breast tumor relapse. No distant recurrence was documented. Cosmetic results were excellent in 94% of patients. Conclusions: Our phase II multicenter study of RFA without resection for early breast cancer will evaluate the long-term safety and efficacy of RFA as well as its cosmetic results, which are a perceived advantage of this technique. Clinical trial information: UMIN000008675.

Clinical